Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer

Completed

Conditions studied: Non Small Cell Lung Cancer

In brief

With roughly 80% of cancer patients receiving their oncology care in the community setting, the investigators are proposing to sample from a community-based center to evaluate the percentage of epidermal growth factor receptor (EGFR)-wild type patients that gain benefit from erlotinib and assess the clinical characteristics that are associated with erlotinib-responders. Additionally, biopsy specimens from enrolled patient cases that are EGFR-wt will be evaluated via exploratory genetic analysis for correlated markers.

Key facts

Study ID

NCT01522833

Run by

SCRI Development Innovations, LLC

People needed

27

Starts

2012-10-01

Expected to finish

2015-02-01

Last updated by the study team

2016-03-07

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have had NSCLC.
• Patients must have received erlotinib (single-agent) for six months or longer for NSCLC in the second/third line setting or as maintenance therapy.
• Patients must have tissue available for EGFR-mutation status testing (if not previously performed) or EGFR-mutation status test results available.
• Patients must have tissue available for exploratory genetic analysis.
• Patients must have all clinical information, treatment response data and outcomes data available for review.
• Patients must be deceased.

Where it is running

• Tennessee Oncology, PLLC — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.